Elenestinib for Healthy Subjects

This trial explores how a new treatment, elenestinib, interacts with other medications in the body. Researchers aim to understand how elenestinib affects the processing of midazolam (a sedative) and a common birth control pill (containing levonorgestrel and ethinyl estradiol). The trial seeks healthy adult women who are non-smokers and have no significant medical issues. Participants should not have used cannabis recently or have any allergies to the trial medications. As a Phase 1 trial, this research focuses on understanding how elenestinib works in people, offering participants the unique opportunity to be among the first to receive this new treatment.

Yes, you will need to stop taking any prescription or non-prescription medications, herbal remedies, or vitamin supplements starting 14 days before the trial. Additionally, you must avoid certain drugs that affect specific enzymes and hormones for a longer period before the trial.

Research has shown that elenestinib is generally safe for people. In earlier studies, most side effects were mild, such as minor stomach upset or headaches, and were the least severe types of side effects. Importantly, no serious side effects were reported, and no participants had to stop taking the drug because of them. This suggests that elenestinib might be safer than other similar treatments. Participants in those studies continued their treatment without major issues, indicating good safety.¹²³⁴⁵

Elenestinib is unique because it is being studied in combination with Midazolam and Levonorgestrel/Ethinyl Estradiol to understand its interactions and effects in healthy individuals. Researchers are particularly excited about Elenestinib due to its potential as a novel therapeutic agent with a new mechanism of action that sets it apart from existing drugs. Unlike current treatments that may focus on a singular pathway, Elenestinib could offer insights into broader pharmacological interactions, providing a more comprehensive understanding of its safety and efficacy profile.

Research has shown that elenestinib is a promising treatment for a specific genetic change called KIT D816V. This change often links to conditions like systemic mastocytosis, where the body produces too many mast cells, a type of white blood cell. Studies have found that elenestinib can reduce the number of these cells and improve symptoms in patients. Most side effects have been mild, indicating good tolerance. Although the current trial involves healthy volunteers receiving elenestinib, these findings suggest that elenestinib could be effective for conditions related to the KIT D816V mutation.¹²³⁶⁷